Cargando…
Mebendazole stimulates CD14+ myeloid cells to enhance T-cell activation and tumour cell killing
Mebendazole (MBZ) was recently shown to induce a tumor suppressive M1 phenotype in THP-1 monocytes and macrophages. In the present study the immune effects of MBZ was further investigated using human peripheral blood mononuclear cells (PBMCs) co-cultured with tumour cells. The Biomap platform was us...
Autores principales: | Rubin, Jenny, Mansoori, Sharmineh, Blom, Kristin, Berglund, Malin, Lenhammar, Lena, Andersson, Claes, Loskog, Angelica, Fryknäs, Mårten, Nygren, Peter, Larsson, Rolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089388/ https://www.ncbi.nlm.nih.gov/pubmed/30112108 http://dx.doi.org/10.18632/oncotarget.25713 |
Ejemplares similares
-
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
por: Blom, Kristin, et al.
Publicado: (2019) -
Mebendazole is unique among tubulin-active drugs in activating the MEK–ERK pathway
por: Andersson, Claes R., et al.
Publicado: (2020) -
Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
por: Selvin, Tove, et al.
Publicado: (2023) -
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
por: Mansoori, S., et al.
Publicado: (2021) -
Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
por: Nygren, Peter, et al.
Publicado: (2013)